Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Revealing oncogenic enhancer regulation by epigenomic profiling of multiple myeloma and plasma cell leukemia patient samples

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAlexia Katsarou

Discussion

Loading...

Member takes

Overview

Analysis uncovers chromatin remodeling and enhancer activity in plasma cell leukemia, highlighting the role of transcription factors and histone modifications.

Key Points

  • Plasma cell leukemia showed distinct alterations in epigenetic landscapes, impacting critical oncogenes involved in tumor growth.
  • Transcription factors, including IRF4 and MYC, displayed varied binding patterns relative to histone modifications in patient samples.
  • Analysis utilized chromosome conformation capture to reveal interactions between enhancers and promoters, emphasizing regulation complexity.
  • These findings underscore the necessity for accurate models to reflect the epigenomic architecture of multiple myeloma.

Cite This Study

Alexia Katsarou (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e558https://doi.org/10.1182/blood-2025-3258
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma2025
  2. 2Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma.2025
  3. 3Diagnosis and prediction of precursor states in multiple myeloma using cell-free chromatin2025
  4. 4Clone-specific epigenetic regulatory mechanisms in ASXL1-mutant chronic myelomonocytic leukemia2025
  5. 5Single-cell chromatin profiling reveals early epigenetic reprogramming, subtype-specific regulatory networks, and JAK/STAT–IRF vulnerabilities in high-risk chronic myeloid leukemia2025